Sort by
Refine Your Search
-
unique opportunity to be an integral part of a dynamic, multifaceted research programme, with reciprocal interdisciplinary engagement between themes (Genomics, Metabolomics, Advanced Medical Imaging
-
collaborative scientists and external companies. Candidates must hold or expect to shortly obtain a PhD, or equivalent in Chemistry, Chemical Engineering or similar Science / Engineering degree and/ or have a
-
contract initially for 18 months, extendable up to 3 years contingent upon successfully meeting project milestones. What you should have: • PhD (or nearing completion) or equivalent industry experience in
-
lead on, plan, develop and conduct individual and/or collaborative research objectives, projects and proposals either as an individual or as part of a broader programme. To acquire, analyse, interpret
-
(MASI)” involving four UK universities (Nottingham, Cardiff, Cambridge, and Birmingham) and join the Computational Materials Science group led by Prof. Elena Besley (https://ebesley.chem.nottingham.ac.uk
-
and closely with other members of the project team. About you We are looking for a motivated, highly qualified individual with a PhD in criminology, law, social sciences or a cognate discipline, who
-
CRISPR-CAS9 gene editing using rodent malaria parasites, cutting edge cell biology, phosphorylation assay and phosphor-proteomics. Candidates must hold a PhD, (awarded or pending) or equivalent in a
-
opportunities for collaboration. About You The candidate must have obtained a PhD degree within 3 years and in the relevant areas being recruited to; Excellent oral and written communication skills in English
-
Applicants must have a PhD or equivalent in a relevant subject (or close to completion). Your work will be supported by Dr Simon Bishop and Professor Alex Trautrims at the University of Nottingham. The person
-
“Supramolecular RNA therapeutics (SMRTs) - developing tunable formulations with scale-independent manufacture” funded by InnovateUK under the “Innovative technologies for intracellular drug delivery” programme. The